Bell County water restrictions could be ending soon
BELL COUNTY, Texas (FOX 44) – The Bell County Water Control & Improvement District #1 (WCID 1) has released an update regarding reduced water supply during completions of critical projects.
General Manager Ricky Garrett has reported that the two projects planned and funded to bring about improved reliability and enhanced resiliency are nearing completion, and critical tie-ins have been completed. Disinfection and line filling started taking place at 2 p.m. Friday. The drought restrictions are recommended to remain in place until midnight, with full service resuming after midnight on Saturday.
Garrett says the drought restrictions which have allowed the past four days of work to proceed without resulting in any boil advisories should be credited to the residents and businesses that curtailed water usage – in some cases at considerable expense for the greater good of the community.
This comes after WCID 1 said earlier this month that it would be requesting a 30 percent reduction in water use beginning at 6 p.m. on May 26th. Two projects planned and funded to bring about improved reliability and enhanced resiliency required a shut down of a 48-inch line to make final connections. This water main delivers approximately two-thirds of the total water supply to the cities of Nolanville, Harker Heights, Killeen, and Copperas Cove – along with the 439 Water Supply Corporation and Fort Cavazos.
PREVIOUS STORY: Ongoing Bell County projects to cause reduced water supply
A bid was awarded to McLean Construction in Killeen on April 24, 2024, in order to constructapproximately 5,000 feet of 54-inch steel pipeline parallel and adjacent to the problem-riddledsection of 48-inch concrete steel cylinder pipe. Since the 48-inch pipe was originally installed in1975, there have been several main breaks resulting in reduced water supply to the approximate 265,000 population served by this system.
WCID 1 said all but one line rupture occurred within a 5,000-foot section of the pipeline near North Nolan Road on the east side of the Fort Cavazos Military Reservation. The new steel pipe section was completed except for the connections to the existing 48 inch on either end.
The other project was the construction of a three million-gallon concrete storage tank a few miles west of the parallel line construction. This bid was also awarded to DN Tanks at the April 2024 WCID 1 Board Meeting. This project also required a shutdown of the 48 to make the necessary connections to the transmission main.
WCID 1 said it would be initiating Stage 3 of its Drought Contingency Plan toward the end of May, seeking at least a 30 percent reduction in water usage. The district asked all of its customers to implement the stage of their own Drought Contingency Plans resulting in at least a 30 percent reduction in water use.
For more information, you can contact Garrett at (254) 501-9243, or send an email to general@wcid1.org.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Regeneron price target lowered to $650 from $700 at Citi
Citi analyst Geoff Meacham lowered the firm's price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi. Confident Investing Starts Here:
Business Insider
5 hours ago
- Business Insider
Regeneron announces analyses from Phase 3 C-Post trial
Regeneron (REGN) Pharmaceuticals announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo in patients with high-risk cutaneous squamous cell carcinoma, CSCC, after surgery. The results, shared during an oral session at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in the New England Journal of Medicine, NEJM, include additional data for the primary endpoint of disease-free survival, DFS, and the first presentation of key secondary endpoint outcomes. With a median duration of follow-up of 24 months, efficacy results for Libtayo compared to placebo, were as follows: 68% reduction in the risk of disease recurrence or death, with median DFS not reached for Libtayo-treated patients; At two years, DFS was 87% with Libtayo versus 64% with placebo; 80% reduction in the risk of locoregional recurrence; 65% reduction in the risk of distant recurrence
Business Insider
5 hours ago
- Business Insider
Arcus Biosciences presented data for casdatifan plus cabozantinib
Arcus Biosciences (RCUS) presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Arcus is pursuing a broad development program in both the immuno-oncology-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Confident Investing Starts Here:
